ENDORSED BY EORA
EMIRATES ONCOLOGY AND RADIOTHERAPY ASSOCIATION
جمعية الإمارات للأورام والعلاج الإشعاعي

1ST EMIRATES HEMATOLOGY FORUM | 31 OCTOBER, 2026 | ROSEWOOD | ABU DHABI

UP TO 7 CME HOURS
ACCREDITATION EXPECTED FROM DUBAI HEALTH AUTHORITY

AGENDA

08:00 - 09:00	Registration & Networking	
09:00 - 09:05	Opening Remarks	Dr Ajlan Al-Zaki
09:05 - 09:15	Rahma Cancer Patient Care Society	
09:15 - 09:35	Keynote: Hemophagocytic Lymphohistiocytosis Management	Dr Swaminathan Iyer
09:35 - 09:50	IEC-HS Case Presentation	Dr Ajlan Al-Zaki
SESSION 1 **Rewriting the Myeloma Playbook | Plasma Cell Disorders from Frontline to Relapse** Moderator: Dr Naser Al Zein		
09:50 - 10:05	CAR-T Cell Therapy in Multiple Myeloma: From Ide-cel to Cilta-cel and Emerging Cellular Therapies	Dr Nausheen Ahmed
10:05 - 10:20	Bispecific T-Cell Engager Therapies: The Role of BiTEs in Hematologic Malignancies	Dr Panagiotis Kaloyannidis
10:20 - 10:35	Management of ADCs in Multiple Myeloma	Dr Aisha Al Aleeli
10:35 - 10:55	**Panel Discussion:** **Sequencing of Myeloma Therapies: Taking Your First BiTE Or Driving Your First CAR-T**	Moderator: Dr Ajlan Al-Zaki Panelists: Dr Nausheen Ahmed Dr Panagiotis Kaloyannidis Dr Emmanouil Nikolousis
10:55 - 11:20	TBC	TBC
11:20 - 11:35	TBC	TBC
11:35 - 11:50	**Networking Coffee Break**	
SESSION 2 **Cells as Medicine | Lymphoma & Leukemia in the CAR-T Era** Moderator: Dr Mansi Sachdev		
11:50 - 12:05	Towards Chemotherapy-Free Frontline Therapy in DLBCL: Are We There Yet?	Dr Husni Al Hateeti
12:05 - 12:20	Role of CAR-T Cell Therapy in Frontline Lymphoma	Dr Fatin Sammour
12:20 - 12:35	Sequencing CAR-T and Bispecific Antibodies in Relapsed/ Refractory Lymphoma: Which Comes First?	Dr Amar Lal
12:35 - 12:50	Peripheral T-Cell Lymphoma: A Practical Approach to Diagnosis and Frontline Management	Dr Reem Al Saadi
12:50 - 13:05	Toxicities Associated with T-Cell Engaging Therapies	Dr Sara Saad
13:05 - 13:20	Toxicities of AML Directed Therapies	Dr Anas Hanini
13:20 - 13:35	Q&A Session	All
13:35 - 13:55	TBC	TBC
13:55 - 14:20	TBC	TBC
14:20 - 15:20	**Networking Lunch Break**	
SESSION 3 **Beyond Chemotherapy | Precision & Time-Limited Therapy in Myeloid Disease** Moderator: Dr Shabeeha Rana		
15:20 - 15:35	More Intense, More Cure? Putting AML Intensity on Trial	Dr Yaser Alkhatib
15:35 - 15:50	MDS in the Frontline Setting: Risk-Adapted Treatment and Emerging Therapeutic Strategies	Dr Noora Obaidallah
15:50 - 16:05	Is Stem Cell Transplantation Still Needed in Frontline ALL?	Dr Arif Alam
16:05 - 16:20	The Evolving Treatment Landscape in CML	Dr Hani Osman
16:20 - 16:40	**Panel Discussion:** **Treatment Failure in Myeloid Malignancies:** **When to Switch Therapy and When to Refer for Transplant**	Moderator: Dr Faraz Khan Panelists: Dr Arif Alam Dr Sana AlBlooshi Dr Yaser Alkhatib Dr Anas Hadidi Dr Noora Obaidallah Dr Hani Osman
16:40 - 16:55	TBC	Dr Yaser Alkhatib
16:55 - 17:10	TBC	TBC
17:10 - 17:25	**Networking Coffee Break**	
SESSION 4 **Beyond the Big Three | Hodgkin, Indolent & T-Cell Lymphomas and Supportive Care in Malignancy** Moderator: Dr Inas El Najjar		
17:25 - 17:40	TBC	TBC
17:40 - 17:55	CART Cell Bleeding and Thrombotic Complications	Dr Julieta Osorio Zuluaga
17:55 - 18:10	BRECADD vs. Nivolumab-AVD in Frontline Hodgkin Lymphoma: Which Strategy for Which Patient?	Dr Preethi Jeyaraman
18:10 - 18:25	Emerging Therapies in Hodgkin Lymphoma: From Novel Immunotherapies to Next-Generation Treatment Strategies	Dr Mohammed Abuhaleeqa
18:25 - 18:40	**Q&A Session**	All
18:40 - 18:45	**Closing Remarks**	Dr Ajlan Al-Zaki

ORGANIZED BY WiredIN